Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352942 | PMC |
http://dx.doi.org/10.1038/s41598-021-95762-5 | DOI Listing |
Cureus
December 2024
Department of Respiratory Medicine, Juntendo University School of Medicine Graduate School of Medicine, Tokyo, JPN.
IgA vasculitis (IgAV) generally occurs in young people and presents with a tetrad of symptoms: purpura, abdominal pain, arthralgia, and nephritis. However, it may have an atypical course without the typical tetrad. Diffuse alveolar hemorrhage (DAH), heart failure, and stroke are known complications of IgAV but are all very rare.
View Article and Find Full Text PDFMod Rheumatol Case Rep
December 2024
Department of Rheumatology, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
Diffuse alveolar hemorrhage (DAH) is a rare and severe complication of IgA vasculitis (IgAV). Although glucocorticoids and immunosuppressive agents are used for its treatment, there is no consensus on the optimal form of treatment. We herein report the case of a 53-year-old, female patient with IgAV.
View Article and Find Full Text PDFCureus
October 2024
Nephrology, Sri Ramaswamy Memorial (SRM) Medical College Hospital and Research Centre, Sri Ramaswamy Memorial (SRM) Institute of Science and Technology, Chengalpattu, IND.
Immunoglobulin A vasculitis (IgAV; initially known as Henoch-Schönlein purpura) is a form of vasculitis involving the small blood vessels of the gastrointestinal tract, skin, joints, and kidney, presenting as a multisystem disorder. A 21-year-old gentleman presented with joint pain, skin rash, abdominal pain, and proteinuria. Biopsies performed from the skin and kidney were both consistent with IgA deposition.
View Article and Find Full Text PDFTurk J Pediatr
November 2024
Department of Pediatrics, Department of Pediatric Rheumatology, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye.
Background: Immunoglobulin A vasculitis (IgAV), the most common systemic vasculitis in children, typically presents with gastrointestinal (GI) symptoms in about half of cases. This study aimed to analyze the clinical and laboratory findings of patients with IgAV regarding GI involvement.
Methods: We compared the GI involvement data of the patients diagnosed with IgAV.
Eur J Pediatr
November 2024
Division of Pediatric Rheumatology, Department of Pediatrics, University of Health Sciences, Ankara Bilkent City Hospital, 06800-Bilkent, Ankara, Turkey.
Unlabelled: The aim of this study was to evaluate the cutaneous manifestations of immunoglobulin A vasculitis (IgAV) in terms of skin lesion type, distribution and persistence and to investigate the relationship between cutaneous manifestations and system involvement and treatment needs. This retrospective observational study was conducted with 489 IgAV patients who were followed-up for at least 6 months between 2013 and 2024. Demographic characteristics, detailed cutaneous manifestations, clinical findings and treatments were retrieved from electronic medical records.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!